'Empathy and love were not shown’: The story behind Taysha’s layoffs, one of dozens of biotechs suffering this year’s bear market
A biotech launched by former AveXis leaders was on a mission to treat multiple rare diseases with new gene therapies. They speedily assembled a team and touted their fast ascent from seed to IPO, in a mere six-month window in 2020, to repeat the playbook they created with the FDA-approved SMA drug Zolgensma.
Flush with a pipeline of more than 25 programs, Taysha Gene Therapies worked in concert with UT Southwestern to take the university’s gene therapy research into the clinic with the ambition of treating monogenic diseases of the central nervous system and pediatric indications. About half a dozen have made it into human trials, with the lead program on track for registration pathway feedback mid-year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
